^(177)Lu标记的前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)放射性配体疗法已在国外获批应用于晚期前列腺癌治疗,且正在国内开展多项临床试验。专家组参考国外经验和观点,并结合国内临床实践和实测数据,形成^(177)Lu-...^(177)Lu标记的前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)放射性配体疗法已在国外获批应用于晚期前列腺癌治疗,且正在国内开展多项临床试验。专家组参考国外经验和观点,并结合国内临床实践和实测数据,形成^(177)Lu-PSMA放射性配体疗法在前列腺癌临床应用中的专家共识。展开更多
This article presents a case of a patient with relapsed esthesioneuroblastoma (ENB), an aggressive rare tumor that arises from the specialized sensory epithelial olfactory cells in the skull base area, which was initi...This article presents a case of a patient with relapsed esthesioneuroblastoma (ENB), an aggressive rare tumor that arises from the specialized sensory epithelial olfactory cells in the skull base area, which was initially treated with endoscopic surgery, followed by adjuvant radiotherapy. After local relapse, new surgical approaches and subsequent lines of platin-based chemotherapy were performed. A PET-CT with <sup>68</sup>GALIUM DOTATATOC (PET-DOTATOC) showed intense uptake of disease, compatible with the presence of somatostatin receptors, in the face, nodes, liver, bones, and meningeal area. Treatment with 4 cycles of <sup>177</sup>Lutetium-Dotatate was performed, followed by maintenance octreotide, with a major radiological and clinical response that is lasting more than 1 year after treatment. This article describes a rare case of a skull-base tumor, with multiple recurrences, in which disease control was achieved with a targeted Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lutetium-Dotatate, and discusses factors that could influence the incorporation of this form of therapy. Previous case reports proved the potential efficacy of this therapy usually given for low-grade neuroendocrine tumors and will be carefully reviewed.展开更多
用离子液体([BSMIm]HSO4、[BSMIm]OTF)代替硫酸进行4,4'-二氨基-1,1'-二蒽醌-3,3'-二磺酸钠(简称DAS)脱磺酸基反应制备颜料红177,考察了离子液体的酸度、离子液体的加入量、反应时间、反应温度及离子液体的循环套用对颜料红...用离子液体([BSMIm]HSO4、[BSMIm]OTF)代替硫酸进行4,4'-二氨基-1,1'-二蒽醌-3,3'-二磺酸钠(简称DAS)脱磺酸基反应制备颜料红177,考察了离子液体的酸度、离子液体的加入量、反应时间、反应温度及离子液体的循环套用对颜料红177收率的影响。离子液体的酸度可以满足DAS脱磺酸基的酸度要求,且离子液体循环套用方便,并且减少工业废水的排放,是一种环境友好的合成工艺。较适宜的工艺条件为:2.0 g DAS,10 g[BSMIm]OTF,反应温度150℃,反应时间5 h,[BSMIm]OTF经二氯甲烷萃取提纯后可至少循环利用6次,颜料红177平均收率为92.3%。展开更多
文摘^(177)Lu标记的前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)放射性配体疗法已在国外获批应用于晚期前列腺癌治疗,且正在国内开展多项临床试验。专家组参考国外经验和观点,并结合国内临床实践和实测数据,形成^(177)Lu-PSMA放射性配体疗法在前列腺癌临床应用中的专家共识。
文摘This article presents a case of a patient with relapsed esthesioneuroblastoma (ENB), an aggressive rare tumor that arises from the specialized sensory epithelial olfactory cells in the skull base area, which was initially treated with endoscopic surgery, followed by adjuvant radiotherapy. After local relapse, new surgical approaches and subsequent lines of platin-based chemotherapy were performed. A PET-CT with <sup>68</sup>GALIUM DOTATATOC (PET-DOTATOC) showed intense uptake of disease, compatible with the presence of somatostatin receptors, in the face, nodes, liver, bones, and meningeal area. Treatment with 4 cycles of <sup>177</sup>Lutetium-Dotatate was performed, followed by maintenance octreotide, with a major radiological and clinical response that is lasting more than 1 year after treatment. This article describes a rare case of a skull-base tumor, with multiple recurrences, in which disease control was achieved with a targeted Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lutetium-Dotatate, and discusses factors that could influence the incorporation of this form of therapy. Previous case reports proved the potential efficacy of this therapy usually given for low-grade neuroendocrine tumors and will be carefully reviewed.
文摘用离子液体([BSMIm]HSO4、[BSMIm]OTF)代替硫酸进行4,4'-二氨基-1,1'-二蒽醌-3,3'-二磺酸钠(简称DAS)脱磺酸基反应制备颜料红177,考察了离子液体的酸度、离子液体的加入量、反应时间、反应温度及离子液体的循环套用对颜料红177收率的影响。离子液体的酸度可以满足DAS脱磺酸基的酸度要求,且离子液体循环套用方便,并且减少工业废水的排放,是一种环境友好的合成工艺。较适宜的工艺条件为:2.0 g DAS,10 g[BSMIm]OTF,反应温度150℃,反应时间5 h,[BSMIm]OTF经二氯甲烷萃取提纯后可至少循环利用6次,颜料红177平均收率为92.3%。
